Literature DB >> 24037882

a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III.

Silvia Monticone1, Namita G Hattangady, David Penton, Carlos M Isales, Michael A Edwards, Tracy A Williams, Christina Sterner, Richard Warth, Paolo Mulatero, William E Rainey.   

Abstract

CONTEXT: Primary aldosteronism is a heterogeneous group of disorders comprising both sporadic and familial forms. Mutations in the KCNJ5 gene, which encodes the inward rectifier K(+) channel 4 (G protein-activated inward rectifier K(+) channel 4, Kir3.4), cause familial hyperaldosteronism type III (FH-III) and are involved in the pathogenesis of sporadic aldosterone-producing adenomas.
OBJECTIVE: The objective of the study was to characterize the effects of a newly described KCNJ5 mutation in vitro. PATIENTS AND METHODS: The index case is a 62-year-old woman affected by primary aldosteronism, who underwent left adrenalectomy after workup for adrenal adenoma. Exon 1 of KCNJ5 was PCR amplified from adrenal tissue and peripheral blood and sequenced. Electrophysiological and gene expression studies were performed to establish the functional effects of the new mutation on the membrane potential and adrenal cell CYP11B2 expression.
RESULTS: KCNJ5 sequencing in the index case revealed a new p.Y152C germline mutation; interestingly, the phenotype of the patient was milder than most of the previously described FH-III families. The tyrosine-to-cysteine substitution resulted in pathological Na(+) permeability, cell membrane depolarization, and disturbed intracellular Ca(2+) homeostasis, effects similar, albeit smaller, to the ones demonstrated for other KCNJ5 mutations. Gene expression studies revealed an increased expression of CYP11B2 and its transcriptional regulator NR4A2 in HAC15 adrenal cells overexpressing KCNJ5(Y152C) compared to the wild-type channel. The effect was clearly Ca(2+)-dependent, because it was abolished by the calcium channel blocker nifedipine.
CONCLUSIONS: Herein we describe a new germline mutation in KCNJ5 responsible for FH-III.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24037882      PMCID: PMC3816265          DOI: 10.1210/jc.2013-2428

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells.

Authors:  Silvia Monticone; Namita G Hattangady; Koshiro Nishimoto; Franco Mantero; Beatrice Rubin; Maria Verena Cicala; Raffaele Pezzani; Richard J Auchus; Hans K Ghayee; Hirotaka Shibata; Isao Kurihara; Tracy A Williams; Judith G Giri; Roni J Bollag; Michael A Edwards; Carlos M Isales; William E Rainey
Journal:  J Clin Endocrinol Metab       Date:  2012-05-24       Impact factor: 5.958

2.  Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5.

Authors:  Ute I Scholl; Carol Nelson-Williams; Peng Yue; Roger Grekin; Robert J Wyatt; Michael J Dillon; Robert Couch; Lisa K Hammer; Frances L Harley; Anita Farhi; Wen-Hui Wang; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis.

Authors:  Kenji Oki; Maria W Plonczynski; Milay Luis Lam; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

4.  A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension.

Authors:  Evangelia Charmandari; Amalia Sertedaki; Tomoshige Kino; Christina Merakou; Dax A Hoffman; Michael M Hatch; Darrell E Hurt; Lin Lin; Paraskevi Xekouki; Constantine A Stratakis; George P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  2012-05-24       Impact factor: 5.958

5.  KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism.

Authors:  Paolo Mulatero; Philipp Tauber; Maria-Christina Zennaro; Silvia Monticone; Katharina Lang; Felix Beuschlein; Evelyn Fischer; Davide Tizzani; Anna Pallauf; Andrea Viola; Laurence Amar; Tracy Ann Williams; Tim M Strom; Elisabeth Graf; Sascha Bandulik; David Penton; Pierre-François Plouin; Richard Warth; Bruno Allolio; Xavier Jeunemaitre; Franco Veglio; Martin Reincke
Journal:  Hypertension       Date:  2011-12-27       Impact factor: 10.190

6.  K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.

Authors:  Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton
Journal:  Science       Date:  2011-02-11       Impact factor: 47.728

Review 7.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

8.  A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.

Authors:  David S Geller; Junhui Zhang; Max V Wisgerhof; Cedric Shackleton; Michael Kashgarian; Richard P Lifton
Journal:  J Clin Endocrinol Metab       Date:  2008-05-27       Impact factor: 5.958

  8 in total
  31 in total

Review 1.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

Review 2.  Insights from exome sequencing for endocrine disorders.

Authors:  Christiaan de Bruin; Andrew Dauber
Journal:  Nat Rev Endocrinol       Date:  2015-05-12       Impact factor: 43.330

3.  Na/K Pump Mutations Associated with Primary Hyperaldosteronism Cause Loss of Function.

Authors:  Dylan J Meyer; Craig Gatto; Pablo Artigas
Journal:  Biochemistry       Date:  2019-03-14       Impact factor: 3.162

Review 4.  Familial hyperaldosteronism type III.

Authors:  S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero
Journal:  J Hum Hypertens       Date:  2017-04-27       Impact factor: 3.012

5.  Channels and pumps in aldosterone-producing adenomas.

Authors:  Celso E Gomez-Sanchez
Journal:  J Clin Endocrinol Metab       Date:  2014-04       Impact factor: 5.958

Review 6.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

7.  Molecular and Electrophysiological Analyses of ATP2B4 Gene Variants in Bilateral Adrenal Hyperaldosteronism.

Authors:  Namita Ganesh Hattangady; Jessica Foster; Antonio Marcondes Lerario; Daniela Ponce-Balbuena; Juilee Rege; Silvia Monticone; William E Rainey; Paolo Mulatero; Tobias Else
Journal:  Horm Cancer       Date:  2020-01-30       Impact factor: 3.869

Review 8.  Hyperaldosteronism: How to Discriminate Among Different Disease Forms?

Authors:  Valentina Crudo; Silvia Monticone; Jacopo Burrello; Fabrizio Buffolo; Martina Tetti; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-02

9.  A Novel Phenotype of Familial Hyperaldosteronism Type III: Concurrence of Aldosteronism and Cushing's Syndrome.

Authors:  Anli Tong; Guanghua Liu; Fen Wang; Jun Jiang; Zhaoli Yan; Dianxi Zhang; Yinsheng Zhang; Jun Cai
Journal:  J Clin Endocrinol Metab       Date:  2016-07-12       Impact factor: 5.958

10.  Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3.

Authors:  Celso E Gomez-Sanchez; Xin Qi; Elise P Gomez-Sanchez; Hironobu Sasano; Martin O Bohlen; Max Wisgerhof
Journal:  Mol Cell Endocrinol       Date:  2016-10-25       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.